- Markets
- Trading
- BALAXI
BALAXI
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Balaxi Pharmaceuticals Expands Global Reach With Hospital Partnerships In Angola
June 25 (Reuters) - Balaxi Pharmaceuticals Ltd BALX.NS:
EXPANDS GLOBAL REACH WITH HOSPITAL PARTNERSHIPS IN ANGOLA AND TENDER BUSINESS SUCCESS IN LATIN AMERICA
Source text for Eikon: [ID:]
Further company coverage: BALX.NS
(([email protected];))
June 25 (Reuters) - Balaxi Pharmaceuticals Ltd BALX.NS:
EXPANDS GLOBAL REACH WITH HOSPITAL PARTNERSHIPS IN ANGOLA AND TENDER BUSINESS SUCCESS IN LATIN AMERICA
Source text for Eikon: [ID:]
Further company coverage: BALX.NS
(([email protected];))
Balaxi Pharmaceuticals To Set Up Pharmaceutical Formulation Plant In A Phased Manner
Feb 9 (Reuters) - Balaxi Pharmaceuticals Ltd BALX.NS:
BALAXI PHARMACEUTICALS LTD - DECIDED TO SET UP PHARMACEUTICAL FORMULATION PLANT IN A PHASED MANNER
BALAXI PHARMACEUTICALS LTD - FIRST PHASE WILL COST AROUND 320 MILLION RUPEES, TAKE 12 MONTHS TO COMPLETE
BALAXI PHARMACEUTICALS - 2ND PHASE OF PLANT WILL INCUR ADDITIONAL COST OF 150 MILLION RUPEES, DOUBLE CAPACITIES OF PLANT FROM 1ST PHASE
Source text for Eikon: ID:nNSE7tYB9b
Further company coverage: BALX.NS
(([email protected];;))
Feb 9 (Reuters) - Balaxi Pharmaceuticals Ltd BALX.NS:
BALAXI PHARMACEUTICALS LTD - DECIDED TO SET UP PHARMACEUTICAL FORMULATION PLANT IN A PHASED MANNER
BALAXI PHARMACEUTICALS LTD - FIRST PHASE WILL COST AROUND 320 MILLION RUPEES, TAKE 12 MONTHS TO COMPLETE
BALAXI PHARMACEUTICALS - 2ND PHASE OF PLANT WILL INCUR ADDITIONAL COST OF 150 MILLION RUPEES, DOUBLE CAPACITIES OF PLANT FROM 1ST PHASE
Source text for Eikon: ID:nNSE7tYB9b
Further company coverage: BALX.NS
(([email protected];;))
Balaxi Pharmaceuticals Approves Set Up Of First Pharmaceutical Formulation Plant At Jadcherla, Hyderabad
May 29 (Reuters) - Balaxi Pharmaceuticals Ltd BALX.NS:
BALAXI PHARMACEUTICALS LTD - APPROVED SET UP OF FIRST PHARMACEUTICAL FORMULATION PLANT AT JADCHERLA, HYDERABAD
Source text for Eikon: ID:nNSE1p9W8f
Further company coverage: BALX.NS
(([email protected];))
May 29 (Reuters) - Balaxi Pharmaceuticals Ltd BALX.NS:
BALAXI PHARMACEUTICALS LTD - APPROVED SET UP OF FIRST PHARMACEUTICAL FORMULATION PLANT AT JADCHERLA, HYDERABAD
Source text for Eikon: ID:nNSE1p9W8f
Further company coverage: BALX.NS
(([email protected];))
Events:
Split
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Balaxi Pharma. do?
Balaxi Ventures Limited is a listed company managing procurement, production, supply chain, distribution, and point of sale for pharmaceutical, food products, and builders hardware through international wholesale trading.
Who are the competitors of Balaxi Pharma.?
Balaxi Pharma. major competitors are Fredun Pharma, Gennex Lab, Trident Lifeline, Lyka Labs, Ambalal Sarabhai Ent, Brooks Laboratories, Zim Laboratories. Market Cap of Balaxi Pharma. is ₹342 Crs. While the median market cap of its peers are ₹322 Crs.
Is Balaxi Pharma. financially stable compared to its competitors?
Balaxi Pharma. seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Balaxi Pharma. pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Balaxi Pharma. latest dividend payout ratio is 1.04% and 3yr average dividend payout ratio is 1.04%
How has Balaxi Pharma. allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is Balaxi Pharma. balance sheet?
Balance sheet of Balaxi Pharma. is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Balaxi Pharma. improving?
The profit is oscillating. The profit of Balaxi Pharma. is ₹27.36 Crs for TTM, -₹7.31 Crs for Mar 2024 and ₹51.74 Crs for Mar 2023.
Is the debt of Balaxi Pharma. increasing or decreasing?
Yes, The debt of Balaxi Pharma. is increasing. Latest debt of Balaxi Pharma. is -₹30.54 Crs as of Sep-24. This is greater than Mar-24 when it was -₹105.14 Crs.
Is Balaxi Pharma. stock expensive?
Balaxi Pharma. is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Balaxi Pharma. is 12.48, while 3 year average PE is 10.35. Also latest EV/EBITDA of Balaxi Pharma. is 8.17 while 3yr average is 11.36.
Has the share price of Balaxi Pharma. grown faster than its competition?
Balaxi Pharma. has given lower returns compared to its competitors. Balaxi Pharma. has grown at ~-23.83% over the last 2yrs while peers have grown at a median rate of 33.28%
Is the promoter bullish about Balaxi Pharma.?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Balaxi Pharma. is 65.99% and last quarter promoter holding is 65.99%.
Are mutual funds buying/selling Balaxi Pharma.?
There is Insufficient data to gauge this.